13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0000882095
Total reported value
$1.6B
$1.6B
6 檔
128.1%
During the Q1 2026 filing period, Gilead Sciences, Inc. (CIK: 0000882095) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $1.6B across 6 reported positions.
In Q1 2026, Gilead Sciences, Inc. adopted a defensive or profit-taking posture, trimming 1 positions and completely liquidating 0 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx Inc | Stock-Other | 36.44% | -36.44% | EXIT | |
| 2 | RCUS | Arcus Biosciences Inc | Stock-Other | 32.05% | +26.71% | — | |
| 3 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 23.67% | +6.67% | — | |
| 4 | ASMB | Assembly Biosciences Inc | Stock-Other | 5.90% | +2.40% | — | |
| 5 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 1.68% | +0.55% | — | |
| 6 | ✓ | Xilio Therapeutics Inc | Stock-Other | 0.26% | +0.12% | -92.86% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx Inc | +13.8% | — | Unchanged |
| 2 | ✓ | Xilio Therapeutics Inc | 0% | -92.86% | Trim |
| 3 | KYTX | Kyverna Therapeutics Inc | -0.3% | — | Unchanged |
| 4 | ASMB | Assembly Biosciences Inc | -2% | — | Unchanged |
| 5 | LKFT | Lakefront Biotherapeutic-adr | -4.8% | — | Unchanged |
| 6 | RCUS | Arcus Biosciences Inc | -6.6% | — | Unchanged |
According to official SEC Form 13F filings, Gilead Sciences, Inc. reported a total U.S. public equity portfolio value of $1.6B across 6 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ACLXGBX, RCUS, LKFT) accounted for 128.1% of total reported equity market value during Q1 2026.
Top Position Liquidated / Trimmed
XILIO THERAPEUTICS INC
前期市值: $5.8M
During Q1 2026, Gilead Sciences, Inc.'s top holdings by market value included ACLXGBX (36.4%)、RCUS (32.0%)、LKFT (23.7%). The largest single position, ACLXGBX, represented 36.4% of total portfolio value.
In Q1 2026, Gilead Sciences, Inc. made 1 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 1 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.